recombinant covid-19 vaccine (chimpanzee adenovirus vector)
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2023 (NCT05706324)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
immunity, active - SARS-CoV-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05706324 | Phase 1 | Jun 30, 2023 | Government of China, National University of Singapore, Wuhan BravoVax Co., Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 1 | 0 | 1 | 2023 |
| National University of Singapore | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Wuhan BravoVax Co., Ltd. | For profit | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1